{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "23401458",
  "DateCompleted": {
    "Year": "2013",
    "Month": "05",
    "Day": "15"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "04",
    "Day": "08"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2013",
        "Month": "02",
        "Day": "11"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1200/JCO.2012.43.9422"
    ],
    "Journal": {
      "ISSN": "1527-7755",
      "JournalIssue": {
        "Volume": "31",
        "Issue": "8",
        "PubDate": {
          "Year": "2013",
          "Month": "Mar",
          "Day": "10"
        }
      },
      "Title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "ISOAbbreviation": "J Clin Oncol"
    },
    "ArticleTitle": "MET as a possible target for non-small-cell lung cancer.",
    "Pagination": {
      "StartPage": "1089",
      "EndPage": "1096",
      "MedlinePgn": "1089-96"
    },
    "Abstract": {
      "AbstractText": [
        "Lung cancer is a heterogeneous group of disorders that is now being subdivided into molecular subtypes with dedicated targeted therapies. The MET receptor tyrosine kinase has been identified as aberrantly overexpressed, potentially having activating mutations, and amplified in certain subsets of lung cancers. The ligand hepatocyte growth factor (HGF) can also be overexpressed in lung cancer or expressed in stroma, and both the MET receptor and the HGF ligand can be targets for therapeutics, especially in lung cancer. Activation of MET leads to a plethora of biochemical and biologic changes both in normal and cancerous cells. Preclinically, it has been shown that silencing or inactivating MET leads to decreased viability of cancer cells. There are a number of compounds against MET/HGF in clinical trials that have been shown to be active in lung cancers. This review will summarize the biology of MET as well as its therapeutic inhibition in lung cancer."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "University of Chicago, Chicago, IL, USA."
          }
        ],
        "LastName": "Sadiq",
        "ForeName": "Ahad A",
        "Initials": "AA"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Salgia",
        "ForeName": "Ravi",
        "Initials": "R"
      }
    ],
    "GrantList": [
      {
        "GrantID": "R01 CA100750",
        "Acronym": "CA",
        "Agency": "NCI NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "R01 CA125541",
        "Acronym": "CA",
        "Agency": "NCI NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "5R01CA125541-05",
        "Acronym": "CA",
        "Agency": "NCI NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "5R01 CA100750-09",
        "Acronym": "CA",
        "Agency": "NCI NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, N.I.H., Extramural",
      "Research Support, Non-U.S. Gov't",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "J Clin Oncol",
    "NlmUniqueID": "8309333",
    "ISSNLinking": "0732-183X"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antineoplastic Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Biomarkers, Tumor"
    },
    {
      "RegistryNumber": "67256-21-7",
      "NameOfSubstance": "Hepatocyte Growth Factor"
    },
    {
      "RegistryNumber": "EC 2.7.10.1",
      "NameOfSubstance": "Proto-Oncogene Proteins c-met"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Antineoplastic Agents"
    },
    {
      "QualifierName": [
        "genetics",
        "metabolism"
      ],
      "DescriptorName": "Biomarkers, Tumor"
    },
    {
      "QualifierName": [
        "drug therapy",
        "genetics",
        "metabolism"
      ],
      "DescriptorName": "Carcinoma, Non-Small-Cell Lung"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Resistance, Neoplasm"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Gene Expression Regulation, Neoplastic"
    },
    {
      "QualifierName": [
        "genetics",
        "metabolism"
      ],
      "DescriptorName": "Hepatocyte Growth Factor"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "drug therapy",
        "genetics",
        "metabolism"
      ],
      "DescriptorName": "Lung Neoplasms"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Mutation"
    },
    {
      "QualifierName": [
        "antagonists & inhibitors",
        "genetics",
        "metabolism"
      ],
      "DescriptorName": "Proto-Oncogene Proteins c-met"
    }
  ],
  "CoiStatement": "Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article."
}